kromastat (NBS-M001) / Nouveau Biosciences - LARVOL DELTA

Anova and Nouveau Biosciences Announce Partnership to Deliver Clinical Trials of Kromastat for the Treatment of Relapsed or Refractory Cutaneous and Peripheral T-Cell Lymphoma (Businesswire) - "The First-in-Human study will be conducted at leading academic medical centers in Australia, with a goal to rapidly move the drug into Phase 2 studies in the U.S. where the company will pursue a 505(b)2 regulatory strategy....Under this partnership, Anova will leverage its AnovaOS platform and comprehensive approach to accelerate clinical development of Kromastat."

First-in-human • Licensing / partnership • Cutaneous T-cell Lymphoma • Peripheral T-cell Lymphoma